ASTH vs. CHE: Which Stock Is the Better Value Option?

Utilizing Zacks Rank and Style Scores, the analysis identifies Astrana Health, Inc. (ASTH) as a superior value investment compared to Chemed (CHE) within the Medical - Outpatient and Home Healthcare sector. ASTH holds a Zacks Rank of #1 (Strong Buy) and a Value Grade of 'A', supported by more attractive valuation metrics including a forward P/E of 14.68, PEG ratio of 0.85, and P/B of 1.74. This contrasts sharply with CHE's Zacks Rank of #4 (Sell), Value Grade of 'C', and higher valuation multiples, positioning ASTH as the preferred option for value-focused investors.

Analysis

A quantitative, value-focused comparison within the Medical Outpatient and Home Healthcare sector positions Astrana Health, Inc. (ASTH) as a more attractive investment relative to Chemed (CHE). The analysis hinges on the Zacks Rank system, which highlights ASTH's superior earnings outlook with a #1 (Strong Buy) rating, indicating positive earnings estimate revisions, in stark contrast to CHE's #4 (Sell) rating. This fundamental strength is complemented by a significant valuation discount. ASTH trades at a forward P/E of 14.68, while CHE is priced at a premium of 20.43. Furthermore, ASTH's PEG ratio of 0.85 suggests its stock price is undervalued relative to its expected earnings growth, whereas CHE's PEG of 2.09 indicates the opposite. The divergence is also evident in their price-to-book ratios, with ASTH at 1.74 and CHE at a much higher 5.83. These metrics collectively earn ASTH a top 'A' grade for Value in the Style Scores system, while CHE receives a 'C', reinforcing the conclusion that ASTH presents a superior value proposition based on current data.

Key Decisions for Investors

• Value-oriented investors should consider Astrana Health (ASTH) as a potential long position, given its strong buy rating, positive earnings revision trends, and compelling valuation metrics including a PEG ratio below 1.0.
• Investors currently holding Chemed (CHE) should re-evaluate their positions due to the combination of a 'Sell' rating, a deteriorating earnings outlook, and premium valuation multiples relative to its peer and growth prospects.
• For sector-focused portfolios, this analysis suggests a potential pair trade of long ASTH and short CHE to capitalize on the diverging fundamental and valuation trajectories within the home healthcare industry.